Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fish oil pill may make 'bad' cholesterol less dangerous, study finds

NCT ID NCT04152291

Knowledge-focused Sponsor: Wihuri Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether taking a high-dose fish oil supplement (E-EPA) for one month changes how LDL ('bad' cholesterol) clumps together in 68 healthy adults. Researchers measured blood fats and LDL stickiness before, during, and after the supplement period. The goal was to understand how E-EPA might lower heart disease risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ethyl eicosapentaenoic acid (E-EPA, also known as icosapent ethyl)
What this could lead to
If it works, this could help explain how E-EPA lowers heart disease risk by making LDL particles less sticky.
What could go wrong
This is a small, early-stage study in healthy people, not patients. Results may not apply to those with high cholesterol or heart disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

68 people

The number who actually took part.

Started

Nov 2019

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy normolipidemic Exclusion Criteria: * Prescription of blood thinner medicine * Circulating Low-density lipoprotein \> 5mmol/l, Triglycerides \>3mmol/l * Chronic use of pain medication * Fish allergy * Pregnancy * Breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis cardiovascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherosclerosis Cardiovascular diseases Low-density lipoprotein lipid composition Low-density lipoproteins aggregation susceptibility

Contacts and locations

Locations

  • Wihuri Research Institute

    Helsinki, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.